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Abstract
Background: A global pandemic mortality study found prominent regional mortality variations in 2009 for Influenza
A(H1N1)pdm09. Our study attempts to identify factors that explain why the pandemic mortality burden was high in
some countries and low in others.
Methods: As a starting point, we identified possible risk factors worth investigating for Influenza A(H1N1)pdm09
mortality through a targeted literature search. We then used a modeling procedure (data simulations and regression
models) to identify factors that could explain differences in respiratory mortality due to Influenza A(H1N1)pdm09. We
ran sixteen models to produce robust results and draw conclusions. In order to assess the role of each factor in
explaining differences in excess pandemic mortality, we calculated the reduction in between country variance, which
can be viewed as an effect-size for each factor.
Results: The literature search identified 124 publications and 48 possible risk factors, of which we were able to identify
27 factors with appropriate global datasets. The modelling procedure indicated that age structure (explaining 40% of
the mean between country variance), latitude (8%), influenza A and B viruses circulating during the pandemic (3–8%),
influenza A and B viruses circulating during the preceding influenza season (2–6%), air pollution (pm10; 4%) and the
prevalence of other infections (HIV and TB) (4–6%) were factors that explained differences in mortality around the
world. Healthcare expenditure, levels of obesity, the distribution of antivirals, and air travel did not explain global pandemic
mortality differences.
Conclusions: Our study found that countries with a large proportion of young persons had higher pandemic mortality
rates in 2009. The co-circulation of influenza viruses during the pandemic and the circulation of influenza viruses during
the preceding season were also associated with pandemic mortality rates. We found that real time assessments of 2009
pandemic mortality risk factors (e.g. obesity) probably led to a number of false positive findings.
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Background
Since the first confirmed death of Influenza A(H1N1)pdm09
in Mexico in April 2009 [1], researchers and public health
officials continue to search for clarity on the global mor-
bidity and mortality impact of Influenza A(H1N1)pdm09
and its associated risk factors, in order to improve future
pandemic response. At the start of an influenza pandemic,
known burden statistics, mostly relating to seasonal influ-
enza, are used to anticipate burden, target pandemic
response, and identify high-risk groups. This can lead to
confusion when real pandemic data slowly comes in and
contradicts this paradigm, leading to stymied response ac-
tivities as the overall risk and factors to mitigate that risk are
poorly understood. We use a standardized estimation meth-
odology to contribute to the evidence base of the global
impact of Influenza A(H1N1)pdm09 and its risk factors.
Our results and approach can be used to provide guidance
for future pandemic response.
Numerous studies have aimed to capture the global
mortality impact of Influenza A (H1N1)pdm09 and iden-
tify factors to explain mortality variations seen across
populations. Studies have focused on familiar risk factors
for seasonal influenza, such as comorbidities [2–14], age
[15–19], pregnancy [20–22], healthcare-related factors
[23, 24], climate [10, 25–28], and treatment approaches
[3, 29–34], while others have explored more obscure risk
factors including pollution exposure [28], pandemic pre-
paredness activities [30, 35], international flight travel
[36], viral shedding [8, 26, 37], and pandemic timing
[30, 36, 38, 39]. These studies have three limitations:
1.) They are typically executed in local hospital or
community settings, limiting the opportunity for com-
parisons across greater communities or countries; 2.)
The number of factors studied is limited – typically only
focusing on a few at once- comorbidities, physiological
factors, or climate for example - not looking at all together;
3.) The definition and method of calculation for influenza
mortality varies, further limiting comparison across studies.
Very few studies have looked at risk factors in multiple
countries [40] and no studies, to our knowledge, have
addressed the above weaknesses. Our study does this by:
a.) Investigating the global Influenza A (H1N1)pdm09
mortality impact within and across all world countries
and the associated risk factors; b.) Including an exhaust-
ive list of possible risk factors believed to be associated
with seasonal and/or pandemic influenza; c.) Using stan-
dardized data collection techniques and source data for
both mortality and risk factors to ensure comparability
across countries. By filling these gaps and strengthening
the data on mortality and risk factors, we hope to fur-
ther the evidence base of pandemic H1N1 risk factors.
The GLaMOR [41] study utilized a standardized ap-
proach to estimate country-specific mortality rates in
200 countries in 2009. Through this approach, the study
found a mortality burden 20× higher than the WHO es-
timate based on laboratory confirmed deaths from May
2010 [42]. In addition, the study found prominent re-
gional mortality variations, proving the highest burden
in the Americas and the lowest burden in Europe, an al-
ternative to a study which found the highest burden in
Africa and South-East Asia [43].
Inspired by the GLaMOR study’s findings and the stan-
dardized method utilizing global data, we combine the ap-
proach, including additional data on risk factors to
determine the contribution of each risk factor on observed
regional variations. In addition, we are able to confirm or
dispute the impact of risk factors long believed to influ-
ence influenza mortality, such as pregnancy and obesity.
This is the first study to investigate the role of multiple
risk factors for H1N1 mortality at the global level using
country-specific data in multiple countries.
Methods
Risk factor literature search
As a starting point, we identified possible risk factors
worth investigating for Influenza A(H1N1)pdm09 mor-
tality through a targeted literature search in Pubmed, fo-
cusing on 2000–2013. Chosen search terms included,
“pH1N1 influenza mortality”, “pandemic influenza
deaths”, “pandemic H1N1 risk factors”, “pandemic influ-
enza severity”, “pandemic influenza outcomes”, “influenza
risk factors”, and numerous variations on those search
terms. Papers solely evaluating risk factors for Influenza
A(H1N1)pdm09 as well as those comparing risk factors
for seasonal influenza or previous influenza pandemics
with Influenza A(H1N1)pdm09 were included. In
addition, papers speculating on certain risk factors were
also included as long as there was sufficient and plausible
justification for the assumption.
Identified risk factors were then categorized into areas
such as “physiological”, “environmental”, and “pandemic
preparedness” as examples. Using these risk factors to
guide the search, we then set out to identify global, public
data sources, which contained comprehensive country-
specific data for the whole world, such as WHO, the
World Bank, and the UN.
Risk factor data sources
Of the possible risk factors captured during the litera-
ture search, we identified appropriate data for approxi-
mately half of the factors. Criteria used to determine if
data for each factor were sufficient for our approach
were the following: a.) Identify enough data from one
global source for at least 50 countries, b.) Data identified
had to include data for all (most) 20 countries included
in the first step in our model (explained below), c.) Data
identified had to include countries from all continents
and WHO regions, to ensure it was regionally diverse
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and not biased to one region d.) Data identified had to
give values, which varied, determined through mean,
variance, and standard deviation calculations.
Data sources for the factors in the analysis included
the WHO Global Health Observatory Data Repository
[44], the World Bank open data database [45], the
WHO FluNet database [46], the IMS Health Antiviral
purchasing database 2007–2009 [31], and the Global
Asthma Report 2011 [47].
Modelling
The global estimates of pandemic mortality in 2009 were
based on 20 observed country excess mortality rates
(these were modelled estimates based on weekly ob-
served data) and 170 country estimates based on a simu-
lation approach [41].
We used the GLaMOR modelling approach to com-
pare the relation between a risk factor and the excess
pandemic mortality under two conditions: the factor is
present and the factor is absent. Because 170 country ex-
cess rates are calculated based on a simulation proced-
ure, it is easy to calculate the excess rates under these
two conditions (present or absent in the data creation
process). The approach is similar to comparing a control
group with an experimental group.
The full procedure can be summarized as follows:
Step 1: Identify the potential risk factors that will be
tested in the model – literature review and the direction
of the effect (see above)
Step 2: Generate data for every country with missing
pandemic mortality estimates using the GLaMOR
simulation approach [41] twice:
(1).Without the potential risk factor of interest e.g. total
health expenditure
(2).With the potential risk factor of interest e.g. total
health expenditure
Step 3: Assess whether there is an association between
the risk factor and the GLaMOR generated pandemic
mortality data
– For all countries, regress (=3) the risk factor with
the GLaMOR generated data from (1)
– For all countries, regress (=4) the risk factor with
the GLaMOR generated data from (2)
Step 4: Examine the relation of the risk factor with the
pandemic mortality data
1. Check how the regression coefficients vary between
(3) and (4)? For example, if (3) is not significant and
(4) is significant, the risk factor may be significant
(see the Decision Rule Set (see: Additional file 1
- Technical Appendix) for all possibilities)
2. Check the direction of the association (the regression
coefficient 4)) based on the published literature. If the
direction is wrong, then the association of the
risk factor is considered to be not a determinant
(association only)
3. Check the association is not driven by age (as age is
associated with many of the factors that are being
assessed). This is done by re-running the regressions
with the two age confounders (% under 15 and %
over 60) to control for these artifacts. If the association
remains it is considered a determinant and if it
disappears (see Additional file 1 - Technical
Appendix for procedure) the risk factor has no
association
Step 5: Repeat the steps 2, 3, 4 16 times using different
data generation procedures (see below, ‘Robustness
assurance’)
Step 6: Credibility of the association for each risk factor
is established by looking at the number of times a relation
(no effect, association or determinant) is found. The
relative effect is established by looking at the average
reduction in the between country variance. (see below,
‘Analysis of pandemic mortality, between country variance’)
This procedure fits very well within Rubin’s Causal In-
ference Model [48], a model which has been used in a
number of public health studies [49, 50]. Central to this
approach is an outcome comparison under two condi-
tions with and without the risk factor, and we have cre-
ated a Decision Rule Set to classify each factor as: no
effect, association effect or determinant effect (see
Additional file 1).
Robustness assurance
For the GLaMOR study [41], the mortality estimation
step using the imputation method was run twice, once
for the age group <65 and once for all ages, so there
were two results per country. For the current analysis, in
order to ensure robust results and conclusions, we ran
16 different variations of the GLaMOR modeling
approach: two different algorithms for the data creation
step - the imputation and matching methods, two age
groups (<65 and all ages) and four different predictor
variables sets (see Fig. 1 and Additional file 1). We took
this approach to minimize the possibility of identifying
false or spurious effects.
Analysis of pandemic mortality, between country variance
In order to assess the relative strength of each factor in
explaining differences (an effect size) in excess pandemic
mortality, we calculated the reduction in the between
country mortality variance for each factor. This propor-
tion is a measure of how strong a factor is in capturing
the difference in country variance. It is calculated by
comparing two regressions, based on the datasets in
which the factor was present during the data creation
stage. First the between country variance for the model
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without the factor in the regression model and next the
between country variance with the factor in the model.
The between country variance for the model with the
factor present is then subtracted from the between
country variance for the model without this factor. This
is divided by the between country variance for the model
without this factor and multiplied by 100 resulting in
a percentage. If the percentage is 100%, then all the
differences in excess mortality rates between countries
could be explained by this factor, if it is 0% this fac-
tor cannot explain any difference between countries.
This was done 16 times and the average is reported.
So the effect size for a factor is the average reduction
in between country variance.
Results
Risk factor literature search
The literature search captured 124 publications and identi-
fied 48 possible risk factors (Table 1) worth exploring. The
48 possible risk factors fall into 10 factor categories – envir-
onmental, comorbidities in adults and children, treatment,
viral, healthcare, demographic, data or modeling, pandemic
preparedness activities, and other.
Of the 48 possible risk factors identified, 27 factors
passed the selection criteria listed above giving sufficient
data to ensure optimized model calculations. Factors we
were unable to explore due to insufficient data include
comorbidities in children such as developmental delay,
cerebral palsy, neurological disorders and congenital
heart disease, adult immunosuppression other than HIV
and TB, antiviral use within 48 h, pH1N1 strain vari-
ation by country, case finding methods, and pandemic
preparedness activities. We identified data for 27 factors
and in some cases the data for one factor acted as a
proxy for some of the factors we couldn’t find sufficient
data to explore. For example, we found data for health
expenditure, which acts as a proxy for clinician
awareness, quick access to treatment, and H1N1
knowledge, three factors we were unable to explore
directly. The categories for the 27 factors, the direc-
tion of the believed association, the data measurement
used in the model, the data sources and other details
are listed in Table 2.
Risk factor influence on mortality
The results of the 16 model executions are presented in
Table 3. The first four columns present the type of effect
for each of the 16 models that were run for each vari-
able: no effect (on influenza A(H1N1)pdm09 mortality),
an association, a determinant effect, or a partial deter-
minant effect. The numbers indicate how often a certain
type of effect was found. Given our Decision Rules, it
should be noted that an effect can be counted two times:
a partial association and a partial determinant (see Add-
itional file 1 - Technical Appendix), so the rows can add
up to more then 16. The next two columns are
counts of the direction of the relations that we found
for these tests. The next column indicates our
Fig. 1 Outline of the 16 different GLaMOR modeling approaches with a selection of the method, the age and the dataset
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Table 1 The 48 possible risk factors worth investigating for Influenza A(H1N1)pdm09 mortality through a targeted literature search
in Pubmed (with a focus on 2000–2013)a
Factor type Factor Factor variable Association
highera
Association
lowera
References
Environmental Pollution Particulate matter ✓ [28]
Ozone ✓
Climate Low temperature/low humidity ✓ [10, 25, 26]
Physiological comorbidities
in adults
Immunosuppression
other than HIV
renal disease, chronic disease, cancer, etc. ✓ [5]
Obesity BMI > 30 ✓ [3, 7]
Morbid Obesity BMI > 40 ✓ [44]
Pulmonary Disease COPD, other ✓ [5]
Immunosupression HIV ✓ [57]
TB ✓
HIV on ARTs ✓ [57]
Physiological comorbidities
in children
Neurological Disorders Prevalence in children ✓ [11]
Cerebral Palsy and
developmental delay
✓ [13]
Congenital Heart Disease ✓ [13]
Asthma and immunosupression ✓ [30, 40]
Treatment Antiviral Use Antiviral Drug Distribution ✓ [31]
Antiviral within 48 h. ✓ [23, 28, 30]
Late onset antiviral ✓ [3, 31, 32]
Healthcare Healthcare expenditure Access to healthcare ✓ [23, 24]
Prompt treatment and available options ✓
Physician knowledge and H1N1awareness ✓
Demographics Population age structure Preschool age ✓ [9]
Pediatric patients ✓ [15]
% < 15 ✓ [16]
% > 60 ✓ ✓ [16, 17]
Children at home ✓ [34]
Ethnicity Alaskan/A.Indian/New Zealand aboriginal ✓ [71]
Hipanics and blacks ✓ [13]
Children of S. Asian descent ✓ [16]
pH1N1 Viral Factors Strain variation by country Start of the pandemic ✓ [30, 38, 39]
Pandemic peak ✓
Co-circulation ✓ ✓
Viral shedding/ transmission Longer shedding in younger people ✓ [72]
Longer shedding under optimal climatic
conditions
✓ [26]
Longer shedding in immunocompromised
people
✓ [8, 72]
Longer shedding or higher viral loads in those
with severe disease
✓
Shorter shedding in those treated with antivirals
within 48 h
✓ [8]
Disease severity Pathogenic strains ✓
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expected relation, based on our literature review, and
the final column provides a measure of the impact
the factor has on the difference between countries in
excess mortality rates (captured in the model by the
between country variance).
All three aspects (type, direction, size of the effect)
need to be combined to interpret the results. For ex-
ample, one or two (partial) determinant effects together
with almost no or a few associations probably indicates
the factor did not play a significant role in explaining
mortality differences, especially if the directions of the
effects are different to what is expected (e.g. healthcare
spending).
Of the 27 factors assessed, 9 showed a positive impact
on mortality, either an association or as a determinant.
Of the remaining factors, 10 had no effect in at least 15
out of the 16 model executions. The most consistent
and strongest effects were found for the age structure of
the population, explaining some 40% of the between
country variance. Higher mortality was generally found
in populations with a high percentage of persons aged
<15 and lower mortalities were found in populations
with an increased percentage of persons aged over 60,
although these were more frequently associations. Con-
sidering age is a factor that is probably associated with
several other variables that are related to excess mortal-
ity during the data generation process, it is hard (impos-
sible) to create a dataset in which variation between
countries due to the age distribution is absent. Latitude was
another important variable (mean proportion explained
variance of 7.8%), but there were mostly associations (rather
than ‘determinant’ or ‘partial determinant’ effects) and most
of the effect was probably the result of (low) mortality rates
in Europe and the Northern Asian countries.
Other important determinant factors were the influ-
enza types (A and B), both during the second half of
2009 and during the previous season, factors related to
other infections (HIV, TB, lower respiratory deaths) and
other respiratory stressors (pm10). No effect was found
for healthcare spending or the distribution of antivirals.
More detailed results for the different algorithms, ob-
served samples and predictor sets are presented in the
Additional file 1 - Technical Appendix together with the
underlying regression models.
Discussion
Our study investigates possible risk factors for influenza
A H1N1 pandemic mortality in all world countries for
2009 using country data on pandemic respiratory mor-
tality combined with global, standardized data on 27
possible risk factors identified in the literature. Our re-
sults illustrate that factors related to H1N1pdm severity
and death are diverse, including previous and co-
circulation of influenza subtypes, environmental factors,
such as climate (latitude) and pollution, young age, and
immunosuppression (HIV and TB). Latitude is probably
reflective of the low mortality in Europe and Western
Pacific rather than being important on its own. The
other findings are similar in some respects to seasonal
influenza, but different with respect to obesity [4, 7, 51],
pregnancy [52, 53], and comorbidities such as asthma
and COPD [2, 5, 6, 9] where we found no effect.
We found that the most important factor explaining
why some countries were harder hit by influenza
A(H1N1)pdm09 was age. Young age (% of the popula-
tion < 15) contributes to 40% of the between country
mortality variance. This result was not surprising as the
frequency and severity of pH1N1 in younger ages com-
pared to older age groups in seasonal influenza has been
shown in numerous studies [15, 18, 19].
We also found a prominent mortality impact from in-
fluenza subtypes H3N2 and Influenza B when co-
circulating with pH1N1 in 2009 and a protective effect
in countries where H3N2 dominated in 2008. These
Table 1 The 48 possible risk factors worth investigating for Influenza A(H1N1)pdm09 mortality through a targeted literature search
in Pubmed (with a focus on 2000–2013)a (Continued)
Data or modelling issues Variation in case finding
by country
-Clinician awareness ✓
-Diagnostic availability ✓ ✓
-Testing protocol ✓ ✓
-Breadth of surveillance ✓ ✓
Pandemic preparedness
activities
Policies Quarantine ✓ [35]
Activities Treatment, education ✓
Case finding efforts Outreach and method ✓ ✓
Quickness of response Timing to mobilize community ✓ ✓
Other Factors CDC Multiplier [43]
International flight traffic International flights coming and going ✓ [36]
a “Association Higher” indicates those factors that may be risk factors for mortality. “Association Lower” indicates those factors that may be protective against
mortality. Some factors are found to be both risk factors and protective factors in the literature and this is indicated with two check marks in the table
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Table 2 The 27 factors selected from the literature search that were included in the modeling analysis
Factor type Factor Factor measurement
for 2009
# Metric unit Data source No. Countries
with data
Value range or
% – all countries
Value range or
% – stage 1
countries
Stage 1
countries
with data (20)
Environmental Pollution pm10 1 μg/m3 World Bank 167 6.7–156.2 11.7–60.2 ✓
co2 emissions 2 (KT) per
1000
174 0.06–6533.0 15.1–6533.0 ✓
Crowding Pop. Density 3 Per square
km
178 1.75–7125.1 2.9–7125.2
Cold Climate Latitude 4 Absolute
degree
178 0–65 1–56 ✓
Physiological
comorbidities
in adults
Obesity BMI > 30
(% both sexes)
5 % WHO 176 1.1–59.6 4.5–33.5
BMI > 30
(% females)
6 175 19.8–36.3 21.7–29.9 ✓
BMI > 30
(% of males)30
7 175 20.1–32.7 22.7–29.3
Pulmonary
Disease
Female COPD
deaths
8 Per
100,000
173 4–125 7–89 ✓
Male COPD deaths 9 170 8–178 19–118
Immuno-
suppression
%HIV 10 % World Bank 145 0.1–25.9 0.1–17.8 ✓
TB 11 Per 100,00 172 0.8–1193 4.5–808 ✓
% HIV ARTs 12 %HIV *
%HIV ARTS
102 0.004–22.3 0.07–7.5
Physiological
comorbidities
in children
Asthma %13 and 14 yr.
olds with wheeze
13 % Global
Asthma
Report
50 3–28 5.1–28 ✓
Treatment Antiviral Use Kilos of drugs
distributed
2007–2009
14 Per
100,000
IMS 60 0–16.2 0.06–15.1
Kilos of drugs
distributed 2009
15 60 0–16.1 0.05–8.1
Healthcare Healthcare
expenditure
Healthcare
spending as
%GDP
16 % World Bank 173 2.0–16.2 3.9–16.2
Demographics Population
age
% < 15 17 % total
population
World Bank 176 13–50 13–31 ✓
% > 60 18 176 2–30 7–30 ✓
Population
growth
Pregnancy -Crude
birth rate
19 Per 1000 178 8.1–53.2 8.1–21.7 ✓
pH1N1 Viral
Factors
Pandemic
factors
Pandemic Start 20 Weeks (1–
52)
FluNet 81 5–46 5–37 ✓
Pandemic Peak 21 86 15–50 21–46 ✓
Pre and co-
circulation
2008 H3N2
dominance
22 0 or 1
(1= > 50%)
69 34.8 35.3
2008 sH1N1
dominance
23 69 18.8 23.5
2009 H3N2
co-circulation
24 0 r 1
(1= > 1%)
90 46.7 52.6
2009 flu B
co-circulation
25 90 35.6 21.1 ✓
Other CDC multiplier Lower respiratory
deaths
26 Per
100,000
CDC paper 169 3–275 11–107 ✓
International
flight traffic
All registered
take offs
27 Per 1000 World Bank 137 0–9182.4 25.5–9182.4 ✓
Morales et al. BMC Infectious Diseases  (2017) 17:642 Page 7 of 12
findings suggest that a population’s immunological re-
sponse to a virus in the previous or current season (due
to factors like waning immunity or the original antigenic
sin) had an impact on mortality levels in 2009.Vaccine
effectiveness studies have shown that immunological re-
sponses need to be considered when explaining findings,
with persons who were vaccinated in the previous sea-
son having lower vaccine effectiveness rates compared
Table 3 Results of the 27 factors that were assessed in the 16 models
Factor components Results Effect direction
Factor type Factor Factor measurement
for 2009
# No
effect
Association Determinant Partial
determinant
Country
variance
Positive
result
Negative
result
Different than
expected
Environmental Pollution pm10 1 10 3 5 2 4.03 6 0
co2 emissions 2 16 0 0 0 0.48 0 0
Crowding Pop. density 3 12 2 2 0 1.38 4 0
Cold climate Latitude 4 0 16 0 0 8.6 0 16 ✓
Physiological
comorbidities
in adults
Obesity BMI > 30
(% both sexes)
5 15 1 0 0 1 0 1 ✓
BMI > 30
(% of females)
6 14 1 1 0 0.61 1 1 ✓
BMI > 30
(% of males)
7 13 3 0 0 0.86 0 3 ✓
Pulmonary
disease
Female COPD
deaths
8 15 0 1 0 0.82 1 0
Male COPD deaths 9 12 2 2 0 1.57 4 0
Immuno-
suppression
%HIV 10 7 5 4 0 4.26 9 0
%TB 11 11 2 3 0 2.05 5 0
% HIV ARTs 12 14 2 0 0 2.71 2 0 ✓
Physiological
comorbidities
in children
Asthma %13 and 14 yr.
olds with wheeze
13 16 0 0 0 0.81 0 0
Treatment Antiviral use Kilos of drugs
distributed
2007–2009
14 15 0 1 0 2.21 0 1
Kilos of drugs
distributed 2009
15 16 0 0 0 2.57 0 0
Healthcare Healthcare
expenditure
Healthcare
spending as
%GDP
16 14 1 1 0 1.2 1 1 ✓
Demographics Population
age
% < 15 17 0 16 2 2 35.2 16 0
% > 60 18 0 16 3 3 45.13 0 16
Population
growth
Pregnancy -Crude
birth rate
19 11 4 1 0 2.71 0 0
pH1N1 Viral
Factors
Pandemic
factors
Pandemic Start 20 16 0 0 0 1.86 0 0
Pandemic Peak 21 15 1 0 0 2.76 0 1 ✓
Co-
circulation
2008 H3N2
dominance
22 11 0 5 0 5.65 0 5
2008 sH1N1
dominance
23 16 0 0 0 1.62 0 0
2009 H3N2
co-circulation
24 7 0 9 0 8.08 9 0
2009 flu B
co-circulation
25 12 0 4 0 2.99 4 0
Other CDC
multiplier
Lower respiratory
deaths
26 13 1 2 0 1.88 3 0
International
flight traffic
All registered take
offs
27 16 0 0 0 0.49 0 0
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to those who were not vaccinated during the previous
season [37, 54, 55].
Although our study was unable to investigate all co-
morbidities believed to impact influenza mortality, we
did find a strong determinant effect with immune-
compromising chronic infections (HIV prevalence and a
smaller effect for TB) [12, 56, 57]. Finally, we found that
environmental exposures are a risk factor if they are a
burden for the respiratory system e.g. air quality-CO2
and pm10 [28].
We found no association between pandemic mortality in
2009 and factors such as antiviral stockpiling [31, 58, 59],
medical and economic factors (e.g. health expenditure)
[23, 24], international air travel [36], previous circulation
of seasonal H1N1 [37], or the pandemic timing in a
country – the start and peak [27, 30]. We were not
able to analyze all factors and additional factors that
would remain worthy of investigation, include viral and
bacterial co-infection [12], use of antivirals within
48 h [9, 29, 33, 60], preexisting influenza immunity [61],
diabetes, neurological disorders [11, 16], the availability
and use of advanced treatment options such as ECMO
and pandemic preparedness activities and policies [30, 35].
Modelling strategy
Different regression strategies are conceivable to es-
tablish a relation between the risk factors and the esti-
mated excess pandemic mortality rates. A first strategy
would be to base the regression analysis on the 20 ob-
served countries included in the GLaMOR project for
which we calculated a country-specific pandemic mor-
tality estimate based on a standardized approach [41].
However, it is well known from the statistical litera-
ture that such a small sample makes the analysis vul-
nerable to numerous problems and has significant
limitations [62]. For completeness, we have performed
these regressions and present the results in the appen-
dix (see Table C).
A second strategy, using traditional regression pro-
cedures, would relate the country specific excess rates
(20 + 170) estimated using the GLaMOR approach
[41] to a risk factor (or a group of risk factors). This
strategy has two major problems: 1.) If the factor be-
ing investigated was used in the GLaMOR data cre-
ation step (there were 10 “factors” used in the
GLaMOR study) it will very often give a false positive
relation; 2.) If the factor being investigated isn’t
present in the GLaMOR data simulation exercise then
it will probably give a false negative relation (unless
the relation is introduced via another predictor in the
GLaMOR procedure). Therefore, doing a traditional
regression analysis using the GLaMOR data combined
with the identified risk factors variables will lead to
biased results with limited meaning. The most limit-
ing factor of both strategies is that the nature of an
association (association or determinant effect) cannot
be distinguished, a well-known limitation of regres-
sion analysis. To address these different points, we
chose a modeling strategy which uses data simula-
tions and regression models and is based on the
Rubin’s Causal Inference Model [48].
Limitations of our study include
 Inability to study the pandemic in 2010 and it is known
that there was more than one wave with varying
impacts.
 Inability to explore some important factors due to
insufficient data including antiviral use within 48 h
(we only had sales), strain pathogenicity, viral
shedding, co-morbidities in children such as
neurological disorders, morbid obesity, and
pandemic preparedness activities and approaches.
 The validity and comparability of the global datasets.
Some of the 27 factors that were included in our
modeling procedure use global datasets that are not
complete (i.e. do not cover all countries in the world,
see Table 2) or accurate. For example, we used the
WHO FluNet database for the ‘Co-circulation viruses’
factors but the validity and comparability of this dataset
has been questioned by a global spatiotemporal study
[63], with the study finding striking differences in the
proportion of influenza B cases across America, Europe
and Asia which may be explained by different testing
efforts across countries / regions.
 Some of the factors we investigated were intended
to be a proxy for something else. For example,
latitude was a proxy for climate and birth rate was a
proxy for pregnancy and for the number of children
in the household. In addition, there is the possibility
of misinterpretation of our results due to the
influence of age. Countries close to the equator
have a large population of young people compared to
countries in the North. Our data on circulating
strains of influenza during and prior to the pandemic
could be strengthened with more country data to be
entered during the data creation steps of the model
 Although this study gives a clear picture of factors
that created variation in the pandemic excess
mortality between countries, the results should
be confirmed in new studies. Some of the factors
were measured in a very approximate manner, for
instance, the antivirals are based on distribution
data rather than a measure of actual use. Or the
influenza virus surveillance data was only available
for a limited number of countries and the
representativeness of this data was unclear
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(was it a good sample of what is going on in a
county and are they comparable between years
and countries).
Conclusion
The story of pandemic mortality burden variations in
2009 has not been clear. Mostly age, pregnancy, obesity,
and co-morbidities have been used to explain observed
differences, although even these factors continue to be
disputed in the literature [14, 40, 64–68]. Although our
study attempts to simplify the complexity of this topic, it
provides some clarity but also raises some further areas
for analysis. We reconfirm the association of age with
mortality, finding higher mortality in lower age groups
[15, 18, 19]. We also highlight the need to look at environ-
mental exposures which are a burden on the respiratory
system (e.g. air pollution) immune-compromising chronic
infections (e.g. HIV and TB), and the interference of other
influenza types co-circulating or previously circulating
which appear to change the risk of mortality [41].
Possibly the most important result is the relation be-
tween variation in immune response reactions [61],
based on viruses that circulated in previous seasons or
that co-circulated with the 2009 pandemic virus, and
variations in the mortality impact. Considering individ-
uals have different immune responses to influenza virus
infections over time (including following vaccination),
this could explain the age effect of the 2009 pandemic,
when a population was confronted with a new influenza
virus (ignoring the environment and history). Our find-
ings suggest that individuals who always generate a less
optimal immune response to a (specific) influenza infec-
tion had died during previous influenza seasons and
among the elderly this group would be smaller than
among younger individuals. Also, the older had been ex-
posed to more frequent virus infections [61], including
influenza AH1N1 viruses, and this may have protected
this group from the 2009 pandemic virus. In conclusion,
besides general differences in individual responses to in-
fluenza viruses, our study finds that the context (previ-
ous and co-circulation of different types of influenza
virus, other bacterial and viral activity) plays an import-
ant role in defining whether an influenza virus infection
results in death during a pandemic.
These findings have important implications for re-
search and public health actions. Variation in immune
responses to the same infection should be studied not
only in general but also within different contexts (previ-
ous and co-circulation of different types of influenza
virus, other bacterial and viral activity). Our study sug-
gests that vaccine studies should assess the impact of
previous influenza infections (other influenza types), as
in a worst case scenario a vaccine could, potentially, in-
crease the chance of mortality, both at an individual and
at a population level. The findings are probably also rele-
vant to seasonal influenza epidemics and it would be
useful to repeat this analysis on data for the seasonal
mortality impact of influenza.
Interestingly, we found no effect for some factors long
believed to matter, which has implications for future
pandemic planning and response. These factors include
obesity [29, 40], pregnancy [19, 22, 40, 52, 69] and stock-
piling of antivirals [31, 58, 70]. This result does not dis-
miss those risk factors entirely, but should draw
attention to the possibility of identifying false risk factors
through the current practice of monitoring an epidemic
(in real time and at the earliest stages).
In conclusion, besides general differences in individual
responses to influenza viruses, our study finds that the
context (previous and co-circulation of different types of
influenza virus, other bacterial and viral activity) plays
an important role in defining whether an influenza virus
infection results in death during a pandemic. We also
show that identifying mortality risk factors in a pan-
demic is a complex exercise and that real time assess-
ments of the 2009 pandemic, frequently based on data
from one country, probably led to many false positive
findings. Finally, we feel that in the future more sophisti-
cated (statistical) methods using data from multiple
countries, preferably from different continents, should
be used to assess the risk factors of pandemic mortality.
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